Price Alert

Dyne Therapeutics Inc. (DYN)

NASDAQ: DYN · Real-Time Price · USD

12.38

-0.12 (-0.96%)

At close: Aug 15, 2025, 10:18 AM

-0.96% (1D)

Bid	9.03
Market Cap	1.76B
Revenue (ttm)	n/a
Net Income (ttm)	-412.88M
EPS (ttm)	-3.88
PE Ratio (ttm)	-3.19
Forward PE	-3.17
Analyst	Buy

Ask	15.88
Volume	304,389
Avg. Volume (20D)	2,916,941
Open	12.50
Previous Close	12.50
Day's Range	12.36 - 12.68
52-Week Range	6.36 - 47.45
Beta	1.08

About DYN

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol DYN

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for DYN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

+7.72%

Dyne Therapeutics shares are trading higher on pos... Unlock content with Pro Subscription

1 month ago

-8.82%

Dyne Therapeutics shares are trading lower after the company announced a $200 million public offering.

News

2 weeks ago · zacks.com

Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect?

The mean of analysts' price targets for Dyne Therapeutics (DYN) points to a 285.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement amon...

2 weeks ago · benzinga.com

These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss

Dyne Therapeutics Inc DYN reported a loss for the second quarter on Monday.

2 weeks ago · fool.com

Dyne Reports Wider Loss in Fiscal Q2

4 weeks ago · businesswire.com

Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer

TORONTO--(BUSINESS WIRE)--Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a biotech company developing new small molecule therapeutic approaches to improve the treatm...

1 month ago · benzinga.com

Tesla, Progress Software, Dyne Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session

U.S. stock futures were lower this morning, with the Dow futures falling around 0.1% on Tuesday.

1 month ago · seekingalpha.com

Dyne Therapeutics - Emergence As A Superior DM1 / DMD Player Warrants Rating Upgrade

Upgrading Dyne Therapeutics to 'Buy' due to promising late-stage DM1 and DMD drug candidates and significant unmet need in both indications. Recent management changes and a more measured clinical appr...

1 month ago · businesswire.com

Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN

LOS ANGELES--(BUSINESS WIRE)---- $DYN--Dyne Therapeutics Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – DYN.